IsoRay

IsoRay Liabilities

Delisted

The The Liabilities of IsoRay (ISR) as of Nov 4, 2026 is 3.16 M USD. In the previous year, The Liabilities was 3.01 M USD — a change of 5.05% (higher).

Liabilities

3.16 MUSD

YoY

5.05%

Last updated:

In 2022, IsoRay's total liabilities amounted to 3.16 M USD, a 5.05% difference from the 3.01 M USD total liabilities in the previous year.

The IsoRay Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2015
2.22 M USD
Jan 1, 2016
1.70 M USD
Jan 1, 2017
1.67 M USD
Jan 1, 2018
2.43 M USD
Jan 1, 2019
1.74 M USD
Jan 1, 2020
2.98 M USD
Jan 1, 2021
3.01 M USD
Jan 1, 2022
3.16 M USD
The IsoRay Liabilities history
YEARLiabilitiesYoY
3.16 MUSD+5.05%
3.01 MUSD+1.14%
2.98 MUSD+70.84%
1.74 MUSD-28.16%
2.43 MUSD+45.47%
1.67 MUSD-1.99%
1.70 MUSD-23.42%
2.22 MUSD-14.36%
2.59 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IsoRay Stock analysis

What does IsoRay do? The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. IsoRay is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing IsoRay's Liabilities

IsoRay's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating IsoRay's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing IsoRay's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

IsoRay's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in IsoRay’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about IsoRay stock

The Liabilities of IsoRay is 3.16 M USD in 2022.

The Liabilities of IsoRay changed from 3.01 M USD to 3.16 M USD, representing a 5.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities IsoRay since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's IsoRay historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IsoRay

All Key Metrics — IsoRay